Monitoring Agency Report for the quarter ended June 30, 2026

August 13, 2026 The National Stock Exchange of India Ltd BSE Limited Corporate Communications Department Department of Corporate Services “Exchange Plaza”, 5th Floor, Phiroze Jeejeebhoy Towers Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai – 400 001 Mumbai - 400051 Scrip Symbol: RELIGARE Scrip Code: 532915 Subject: Monitoring Agency Report for the quarter ended June 30, 2026 Dear Sir/ Ma’am, Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 162A of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find attached Monitoring Agency Report for the quarter ended June 30, 2026, issued by CARE Ratings Limited, Monitoring Agency, in respect of the utilization of proceeds raised through Preferential Issue of convertible warrants by the Company. This is for information and records. Thanking You, Yours faithfully, For Religare Enterprises Limited Babu Rao P. Group General Counsel & Group Chief Compliance Officer Encl.: As above Religare Enterprises Limited CIN: L74899DL1984PLC146935 Registered Office: First Floor, Office No. 101, 2E/23, Jhandewalan Extn., New Delhi – 110055 Phone No.: +91-11- 4167 9692 Corporate Office: 1st Floor, Tower A, Club 125, Plot A-3,4, 5, Sector -125, Noida – 201301, Uttar Pradesh Phone No.: +91-120- 4384 941 www.religare.com / investorservices@religare.com No. CARE/NRO/GEN/2026-27/1030 The Board of Directors Religare Enterprises Limited First Floor, Office No. 101, 2E/23, Jhandewalan Extn., Swami Ram Tirth Nagar, New Delhi-110055 August 12, 2026 Dear Sir/Ma’am, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Preferential Issue (whichever is applicable) of Religare Enterprises Limited (“the Company”) We write in our capacity of Monitoring Agency for the Preferential Issue for the amount aggregating to Rs. 1,500.00 crore of the Company and refer to our duties cast under Regulation 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations. In this connection, we are enclosing the Monitoring Agency Report for the quarter ended June 30, 2026 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated August 08, 2025. Request you to kindly take the same on records. Thanking you, Yours faithfully, Jatin Arora Associate Director Jatin.arora@careedge.in CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in • www.careedge.in CIN-L67190MH1993PLC07169 Report of the Monitoring Agency Name of the issuer: Religare Enterprises Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: CARE Ratings Limited (a) Deviation from the objects: Not Applicable (b) Range of Deviation: Not Applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Jatin Arora Designation of Authorized person/Signing Authority: Associate Director CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in • www.careedge.in CIN-L67190MH1993PLC07169 1) Issuer Details: Name of the issuer : Religare Enterprises Limited Name of the promoter : Burman Group (M B FINMART PRIVATE LIMITED, MILKY INVESTMENT AND TRADING COMPANY, PURAN ASSOCIATES PVT LTD and VIC ENTERPRISES PRIVATE LIMITED) Industry/sector to which it belongs : Core-Investment Company 2) Issue Details Issue Period : September 12, 2025 to March 11, 2027 (18 months from date of allotment) Type of issue (public/rights) : Preferential issue of Warrants Type of specified securities : Warrants convertible into equity shares IPO Grading, if any : Not Applicable Issue size (in crore) : Rs. 1,500.00 crore 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Comments of Source of information / certifications Comments of the the Particulars Reply considered by Monitoring Agency for preparation of report Monitoring Agency Board of Directors Whether all utilization is as per the disclosures in the Offer Chartered Accountant certificate*, No comments Yes All the proceeds utilized till Jun 30, Document? Management certificate, Bank statements 2026, from warrant issue were as per CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, 4th Floor, Godrej Coliseum, Somaiya Hospital Noida, Road, Off Eastern Express Highway, Sion (East), Gautam Budh Nagar, Uttar Pradesh -201301 Mumbai - 400 022 Phone: +91-120-4452000 Phone: +91-22-6754 3456 Email: care@careedge.in • www.careedge.in CIN-L67190MH1993PLC07169 Comments of Source of information / certifications Comments of the the Particulars Reply considered by Monitoring Agency for preparation of report Monitoring Agency Board of Directors the objectives mentioned in the offer document. In the current quarter, a new loan amounting to Rs. 50 crores was sanctioned and a tranche of Rs. 25 crores was disbursed to RBL. Subsequently, an amount of Rs. 25 crores has been prepaid by RBL in June 2026. Whether shareholder approval has been obtained in case of No comments There has been no deviation observed material deviations# from expenditures disclosed in the Offer Not applicable Not applicable so far. Document? Whether the means of finance for the disclosed objects of the Chartered Accountant certificate*, No comments No No comments issue have changed? Management certificate Chartered Accountant certificate*, No comments Is there any major deviation observed over the earlier monitoring There are no deviations observed [Showing first 8,000 characters — download PDF for full document]